Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
Cosentyx® - IL-17A inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
NCT04930094 (CAIN457R12301)
Giant cell arteritis
Phase 3
240
Arms Intervention
Target Patients
Read-out Milestone(s)
Publication
Number of participants with sustained remission
Experimental: Secukinumab 300 mg Placebo Comparator: Placebo
Patients with Giant Cell Arteritis (GCA)
Primary 2024
Final 2025
TBD
84 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation